FEATURED ARTICLE
MASP2 Antibody Successful in Phase III Clinical Trial
On December 19, 2024, Omeros announced that its pivotal Phase 3 clinical trial of the MASP2 antibody Narsoplimab (OMS721) in the treatment of TA-TMA (Transplant-Associated Thrombotic Microangiopathy) met its primary endpoint of overall survival (OS), with a 3-fold reduction in mortality risk [1]. Omeros stock surged 37% after the press release...
MASP2 Antibody Successful in Phase III Clinical Trial
On December 19, 2024, Omeros announced that its pivotal Phase 3 clinical trial of the MASP2 antibody Narsoplimab (OMS721) in the treatment of TA-TMA (Transplant-Associated Thrombotic Microangiopathy) met its primary endpoint of overall survival (OS), with a 3-fold reduction in mortality risk [1]. Omeros stock surged 37% after the press release...
